This podcast episode discusses the potential benefits of using psilocybin and ibogaine in therapy, particularly for individuals with life-threatening illnesses and drug addiction. Phase two and three trials of psilocybin-assisted therapy include a 12-month follow-up to evaluate its long-term effects.
This podcast episode explains how cholesterol is transported through the bloodstream and why it can't be moved the way water-soluble substances can. The episode also discusses the role of HDL and LDL cholesterol in the body.
Ibogaine, known for its ability to treat opioid addiction, may have a wider anti-addictive and anti-compulsive effect. While opioids have agonist replacement therapies, there are no drugs designed to directly reduce the addictiveness of opioids themselves.
While psychedelic therapy may be transformative for some individuals, there are also concerns about people seeking spiritual awakening through self-administered substances without proper guidance or psychological support. It's important to note that this approach is not one size fits all and should be used under controlled conditions.
The criminalization of drugs needs to be replaced with regulation, focusing on the appropriate level for each individual drug. Thus, the medical research on psychedelics that is currently taking place would still occur even if they had not been made illegal.
Heroin assisted treatment programs have been found to be incredibly successful in helping long-term chronic heroin addicts overcome their addiction, as they treat it like a medical condition in need of help instead of a crime.